Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Quantum Genomics    ALQGC   FR0011648971

QUANTUM GENOMICS

(ALQGC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Quantum Genomics : Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals

10/28/2020 | 02:05am EST

Quantum Genomics to receive up to $11.35 million in upfront and milestone payments plus double-digit royalties on sales

Xediton Pharmaceuticals to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Canada

 

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Xediton Pharmaceuticals to develop and commercialize firibastat in Canada.

Under the terms of the agreement, Xediton Pharmaceuticals will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Canada. Quantum Genomics has already recruited patients in Canada for the pivotal phase III study FRESH.

Quantum Genomics will receive upfront and milestone payments amounting up to $-11.35 million, plus double-digit royalties on sales.

The population suffering from difficult to treat and resistant hypertension in the above territories is estimated to be between 1 and 1.5 million.

“We are proud to partner firibastat with Xediton Pharmaceuticals, a private-held specialty Pharma. We share common values : positively impact the lives of our patients through our products and physicians. With an experienced management team, Xediton Pharmaceuticals is a fully operational company having already three assets in cardiovascular on the market” mentioned Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics.

 “We are very pleased to partner with Quantum Genomics to bring to Canadian patients Firibastat. While there are numerous treatments in hypertension, there is not much available for patients who are resistant to current treatments. We are looking forward to Firibastat being on the market, as it will be of tremendous benefit to patients with difficult to treat/resistant hypertension and heart failure” said George Gafrey, President of XEDITON Pharmaceuticals Inc.

 


About Xediton Pharmaceuticals
Xediton Pharmaceuticals is a privately-held pharmaceutical company with a focus on meeting the needs of patients, physicians and partners. Xediton Pharmaceuticals is committed to developing, partnering and making available new and established medicines to promote the health of Canadians. Located in the Greater Toronto Area, Canada, Xediton Pharmaceuticals has products in Oncology, Anti-Infectives, Pain, GI, Ophthalmology and CV and has built strong strategic alliances with Global and International Healthcare and pharmaceutical companies.
For more information, please visit www.xediton.com

 


About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).
Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).
For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn


Contacts

Quantum Genomics  
Jean-Philippe Milon
CEO
jean-philippe.milon@quantum-genomics.com
Benoît Gueugnon
CFO
benoit.gueugnon@quantum-genomics.com
So Bang (Europe)  
Nathalie Boumendil
Financial Communications
+33 (0)6 85 82 41 95 | nathalie@so-bang.fr
Samuel Beaupain
Media Relations and Scientific Communications
+33 (0)6 88 48 48 02 | samuel@so-bang.fr
LifeSci (USA)  
Dan Ferry
Financial Communications
+1 (617) 535-7746 | Daniel@lifesciadvisors.com
Mike Tattory
Media Relations and Scientific Communications
+1 (609) 802-6265 | mtattory@lifescipublicrelations.com


This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: yW2aaZyZZZuVnm1pZpqanJeXm2dilGidl5WdlJNxaJaYaWlhyG6Wm5yeZm9mnWhn
- Check this key: https://www.security-master-key.com.



Regulated information:
Inside Information:
- Operations of the issuer (acquisitions, sales…)


Full and original press release in PDF: https://www.actusnews.com/news/65831-quantum-genomics_xediton-pr-english-final-version.pdf

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free


© 2020 ActusNews
All news about QUANTUM GENOMICS
11/02QUANTUM GENOMICS : Quantum Genomics Announces End of Financing Agreement with Ne..
AN
11/02QUANTUM GENOMICS : Announces End of Financing Agreement with Negma Group Ltd/Par..
AQ
11/02Quantum Genomics Announces End of Financing Agreement with Negma Group Ltd/Pa..
GL
10/29QUANTUM GENOMICS : enters exclusive licensing and collaboration agreement with X..
AQ
10/28QUANTUM GENOMICS : Quantum Genomics Enters into Exclusive Licensing and Collabor..
AN
10/28QUANTUM GENOMICS : Enters into Exclusive Licensing and Collaboration Agreement w..
AQ
10/28Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement ..
GL
10/20QUANTUM GENOMICS : enters into exclusive licensing and collaboration agreement w..
AQ
10/19QUANTUM GENOMICS : Quantum Genomics Enters into Exclusive Licensing and Collabor..
AN
10/19QUANTUM GENOMICS : Enters into Exclusive Licensing and Collaboration Agreement w..
AQ
More news
Financials
Sales 2020 4,00 M 4,78 M 4,78 M
Net income 2020 -9,99 M -12,0 M -12,0 M
Net cash 2020 8,61 M 10,3 M 10,3 M
P/E ratio 2020 -11,0x
Yield 2020 -
Capitalization 110 M 132 M 132 M
EV / Sales 2020 25,4x
EV / Sales 2021 16,3x
Nbr of Employees 11
Free-Float 90,7%
Chart QUANTUM GENOMICS
Duration : Period :
Quantum Genomics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUANTUM GENOMICS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 16,80 €
Last Close Price 5,20 €
Spread / Highest target 223%
Spread / Average Target 223%
Spread / Lowest Target 223%
EPS Revisions
Managers
NameTitle
Jean-Philippe Milon Chief Executive Officer & Director
Lionel Ségard Chairman
Benoît Gueugnon Chief Financial Officer
Fabrice Balavoine Vice President-Research & Development
Bruno Besse Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
QUANTUM GENOMICS53.85%132
LONZA GROUP AG55.15%44 901
MODERNA, INC.549.44%43 204
CELLTRION, INC.82.04%39 811
IQVIA HOLDINGS INC.9.26%32 568
SEAGEN INC.48.01%29 832